# NCT02025010 (NCT02025010)

> Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: abiraterone
- Indication: castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02025010
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Castration-resistant Prostate Cancer
- Interventions: abiraterone acetate
- Enrollment: 60
- Primary outcome: Number of Participants With Toxicities That Required the Addition of Prednisone to Manage Symptoms of Persistent or Severe Mineralocorticoid Excess

## Indexed commentary on NCT02025010 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02025010